Proteolysis in Carcinogenesis

Head and Neck Cancer: Emerging Perspectives

Volumn , Issue , 2003, Pages 137-149

  Bugge, Thomas H ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0043122745     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012239990-9/50011-4     Document Type: Chapter

References (200)

1. Danø K., Andreasen P.A., Grøndahl-Hansen J., Kristensen P., Nielsen L.S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 1985, 44:139-266.
2. Andreasen P.A., Kjøller L., Christensen L., Duffy M.J. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int. J. Cancer 1997, 72:1-22.
3. Andreassen P.A., Egelund R., Petersen H.H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell. Mol. Life Sci. 2000, 57:25-40.
4. Ellis V., Behrendt N., Danø K. Plasminogen activation by receptor-bound urokinase: A kinetic study with both cell-associated and isolated receptor. J. Biol. Chem. 1991, 266:12752-12758.
5. Cubellis M.V., Andreasen P., Ragno P., Mayer M., Danø K., Blasi F. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc. Natl. Acad. Sci. USA 1989, 86:4828-4832.
6. Ellis V., Wun T.C., Behrendt N., Ronne E., Danø K. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J. Biol. Chem. 1990, 265:9904-9908.
7. Baker M.S., Bleakley P., Woodrow G.C., Doe W.F. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. Cancer Res. 1990, 50:4676-4684.
8. Plow E.F., Freaney D.E., Plescia J., Miles L.A. The plasminogen system and cell surfaces: Evidence for plasminogen and urokinase receptors on the same cell type. J. Cell Biol. 1986, 103:2411-2420.
9. Hall S.W., Humphries J.E., Gonias S.L. Inhibition of cell surface receptor-bound plasmin by alpha 2-antiplasmin and alpha 2-macroglobulin. J. Biol. Chem. 1991, 266:12329-12336.
10. Danø K., Rømer J., Nielsen B.S., Bjorn S., Pyke C., Rygaard J., Lund L.R. Cancer invasion and tissue remodeling: Cooperation of protease systems and cell types. APMIS 1999, 107:120-127.
11. Skriver L., Larsson L.I., Keilberg V., Nielsen L.S., Andreassen P.B. Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J. Cell Biol. 1984, 99:752-757.
12. Pyke C., Kristensen P., Ralfkiaer E., Grøndahl-Hansen J., Eriksen J., Blasi F., Danø K. Urokinase type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon cancer. Am. J. Pathol. 1991, 138:1059-1067.
13. Pyke C., Kristensen P., Ralfkiaer E., Eriksen J., Danø K. The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res. 1991, 51:4067-4071.
14. Pyke C., Graem N., Ralfkier W., Rønne E., Høyer-Hansen G., Brunner N., Danø K. The receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res. 1993, 53:1911-1915.
15. Schmidt M., Schler G., Gruensfelder P., Muller J., Hoppe F. Urokinase receptor up-regulation in head and neck squamous cell carcinoma. Head Neck 2000, 22:498-504.
16. Dublin E., Hanby A., Patel N.K., Liebman R., Barnes D. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology. Am. J. Pathol. 2000, 157:1219-1227.
17. Hudson M.A., McReynolds L.M. Urokinase and the urokinase receptor: Association with in vitro invasiveness of human bladder cancer cell lines. J. Natl. Cancer Inst. 1997, 89:709-717.
18. De Petro G., Tavian D., Copeta A., Portolani N., Giulini S.M., Barlati S. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res. 1998, 58:2234-2239.
19. Morita S., Sato A., Hayakawa H., Ihara H., Urano T., Takada Y., Takada A. Cancer cells overexpress mRNA of urokinase-type plasminogen activator, its receptor and inhibitors in human non-small-cell lung cancer tissue: Analysis by Northern blotting and in situ hybridization. Int. J. Cancer 1998, 78:286-292.
20. Taniguchi T., Kakkar A.K., Tuddenham E.G., Williamson R.C., Lemoine N.R. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. Cancer Res. 1998, 58:4461-4467.
21. Sier C.F., Stephens R., Bizik J., Mariani A., Bassan M., Pedersen N., Frigerio L., Ferrari A., Danø K., Brunner N., Blasi F. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res. 1998, 58:1843-1849.
22. Plesner T., Ralfkiaer E., Wittrup M., Johnsen H., Pyke C., Pedersen T.L., Hansen N.E., Danø K. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am. J. Clin. Pathol. 1994, 102:835-841.
23. Lanza F., Castoldi G.L., Castagnari B., Todd R.F., Moretti S., Spisani S., Latorraca A., Focarile E., Roberti M.G., Traniello S. Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukaemic cells. Br. J. Haematol. 1998, 103:110-123.
24. Pyke C., Ralfkiaer E., Ronne E., Hoyer-Hansen G., Kirkeby L., Danø K. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology 1994, 24:131-138.
25. Nielsen B.S., Sehested M., Timshel S., Pyke C., Danø K. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab. Invest. 1996, 74:168-177.
26. Danø K., Behrendt N., Brunner N., Ellis V., Ploug M., Pyke C. The urokinase receptor: Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994, 9:189-203.
27. Duffy M.J., Reilly D., O'Sullivan C., O'Higgins N., Fennely J.J., Andreassen P.A. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res. 1990, 50:6827-6829.
28. Foekens J.A., Schmitt M., van Putten W.L.J., Peters H.A., Bontenbal M., Janicke F., Klijn J.G.M. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res. 1992, 52:6101-6105.
29. Grøndahl-Hansen J., Christensen I.J., Rosenquist C., Brunner N., Mouridsen H.T., Danø K., Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 1993, 53:2513-2521.
30. Ganesh S., Siene C.E.M., Heerding M.M., Griffioen G., Lamers C.B.H.W., Verspaget H.W. Diagnostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res. 1994, 54:4065-4071.
31. Oka T., Ishida T., Nishino T., Sugimachi K. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. Cancer Res. 1991, 51:3522-3525.
32. Pedersen H., Grøndahl-Hansen J., Francis D., Østerlind K., Hansen H.H., Danø K., Brunner N. Prognostic impact of urokinase, urokinase receptor and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res. 1994, 54:4671-4675.
33. Heinert G., Kircheimer J.C., Pfluger H., Binder B.R. Urokinase-type plasminogen activator as a marker for the formation of distant metastasis in prostate carcinomas. J. Urol. 1988, 140:1466-1469.
34. Heiss M.M., Allgayer H., Gruetzner K.U., Funke I., Babic R., Jauch K.W., Schildberg F.W. Individual development and uPA-receptor expression of disseminated tumor cells in bone marrow: A reference to early systemic disease in solid tumors. Nature Med. 1995, 1:1035-1039.
35. Nekarda H., Siewert J.R., Schmitt M., Ulm K. Tumorassociated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet 1994, 343:117.
36. Kook Y.H., Adamski J., Zelent A., Ossowski L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J. 1994, 13:3983-3991.
37. Yu H., Schultz R.M. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res. 1990, 50:7623-7633.
38. Hearing V.J., Law L.W., Corti A., Apella E., Blasi F. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res. 1988, 48:1270-1278.
39. Kobayashi H., Gotoh J., Shinohara H., Moniwa N., Terao T. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model. Thromb. Haemostasis 1994, 71:474-480.
40. Ossowski L., Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983, 35:611-619.
41. Ossowski L. Plasminogen activator dependent pathways in dissemination of human tumors in the chick embryo. Cell 1988, 52:321-328.
42. Ossowski L., Russo-Payne H., Wilson E.L. Inhibition of urokinase-type plasminogen activator by antibodies: The effect on dissemination of a human tumor in the nude mouse. Cancer Res. 1991, 51:274-281.
43. Crowley C.W., Cohen R.L., Lucas B.K., Liu G., Shuman M.A., Levinson A.D. Prevention of metastasis by inhibition of the urokinase receptor. Proc. Natl. Acad. Sci. USA 1993, 90:5021-5025.
44. Kobayashi H., Gotoh J., Fujie M., Shinohara H., Moniwa N., Terao T. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int. J. Cancer 1994, 57:727-733.
45. Min Y.M., Doyle L.V., Vitt C.R., Zandonella C.L., Stratton-Thomas J.R., Shuman M.A., Rosenberg S. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 1996, 56:2428-2433.
46. Mueller B.M., Yu Y.B., Laug W.E. Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc. Natl. Acad. Sci. USA 1995, 92:205-209.
47. Rabbani S.A., Harakidas P., Davidson D.J., Henkin J., Mazar A.P. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int. J. Cancer 1995, 63:840-845.
48. Shapiro R.L., Duquette J.G., Roses D.F., Nunes I., Harris M.N., Kamino H., Wilson E.L., Rifkin D.B. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: Cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res. 1996, 56:3597-3604.
49. Bugge T.H., Kombrinck K.W., Xiao Q., Holmback K., Daugherty C.C., Witte D.P., Degen J.L. Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. Blood 1997, 90:4431-4522.
50. Bugge T.H., Lund L.R., Kombrinck K.K., Nielsen B.S., Holmback K., Drew A.F., Flick M.J., Witte D.P., Danø K., Degen J.L. Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 1998, 16:3097-3104.
51. Birkedal-Hansen H., Moore W.G., Bodden M.K., Windsor L.J., Birkedal-Hansen B., DeCarlo A., Engler J.A. Matrix metalloproteinases: A review. Crit. Rev. Oral Biol Med. 1993, 4:197-250.
52. McCawley L.J., Matrisian L.M. Matrix metalloproteinases: Multifunctional contributors to tumor progression. Mol. Med. Today 2000, 6:149-156.
53. Pei D., Kang T., Qi H. Cysteine array matrix metalloproteinase (CA-MMP)/MMP-23 is a type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation. J. Biol. Chem. 2000, 275:33988-33997.
54. Brew K., Dinakarpandian D., Nagase H. Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochim. Biophys. Acta 2000, 1477:267-283.
55. Primakoff P., Myles D.G. The ADAM gene family: Surface proteins with adhesion and protease activity. Trends Genet. 2000, 16:83-87.
56. Tang B.L. ADAMTS: A novel family of extracellular matrix proteases. Int. J. Biochem. Cell Biol. 2001, 33:33-44.
57. Werb Z., Vu T.H., Rinkenberger J.L., Coussens L.M. Matrix-degrading proteases and angiogenesis during development and tumor formation. APMIS 1999, 107:11-18.
58. Murray G.I., Duncan M.E., O'Neil P., Melvin W.T., Fothergill J.E. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nature Med. 1996, 2:461-462.
59. Grignon D.J., Sakr W., Toth M., Ravery V., Angulo J., Shamsa F., Pontes J.E., Crissman J.C., Fridman R. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res. 1996, 56:1654-1659.
60. Sier C.F., Kubben F.J., Ganesh S., Heerding M.M., Griffioen G., Hanemaaijer R., van Krieken J.H., Lamers C.B., Verspaget H.W. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br. J. Cancer 1996, 74:413-417.
61. Gohji K., Fujimoto N., Fujii A., Komiyama T., Okawa J., Nakajima M. Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res. 1996, 56:3196-3198.
62. Talvensaari-Mattila A., Paakko P., Hoyhtya M., Blanco-Sequeiros G., Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein: A marker of aggressiveness in breast carcinoma. Cancer 1998, 83:1162-1553.
63. Kanayama H., Yokota K., Kurokawa Y., Murakami Y., Nishitani M., Kagawa S. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 1998, 82:1359-1366.
64. Anderson I.C., Shipp M.A., Docherty A.J.P., Teicher B.A. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res. 1996, 56:715-718.
65. Wilson C.L., Heppner K.J., Labosky P.A., Hogan B.L., Matrisian L.M. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl. Acad. Sci. USA 1997, 94:1402-1407.
66. Sternlicht M.D., Lochter A., Sympson C.J., Huey B., Rougier J.P., Gray J.W., Pinkel D., Bissell M.J., Werb Z. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999, 98:137-146.
67. Coussens L.M., Tinkle C.L., Hanahan D., Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103:481-490.
68. Peschon J.J., Slack J.L., Reddy P., Stocking K.L., Sunnarborg S.W., Lee D.C., Russell W.E., Castner B.J., Johnson R.S., Fitzner J.N., Boyce R.W., Nelson N., Kozlosky C.J., Wolfson M.F., Rauch C.T., Cerretti D.P., Paxton R.J., March C.J., Black R.A. An essential role for ectodomain shedding in mammalian development. Science 1998, 282:1281-1284.
69. Blobel C.P. Remarkable roles of proteolysis on and beyond the cell surface. Curr. Opin. Cell Biol. 2000, 12:606-612.
70. Kaushal G.P., Shah S.V. The new kids on the block: ADAMTSs, potentially multifunctional metalloproteinases of the ADAM family. J. Clin. Invest. 2000, 105:1335-1337.
71. Turk B., Turk D., Turk V. Lysosomal cysteine proteases: More than scavengers. Biochim. Biophys. Acta 2000, 1477:98-111.
72. Koblinski J.E., Ahram M., Sloane B.F. Unraveling the role of proteases in cancer. Clin. Chim. Acta 2000, 291:113-135.
73. Poole A.R., Tiltman K.J., Recklies A.D., Stoker T.A. Differences in secretion of the proteinase cathepsin B at the edges of human breast carcinomas and fibroadenomas. Nature 1978, 273:545-547.
74. Frosch B.A., Berquin I., Emmert-Buck M.R., Moin K., Sloane B.F. Molecular regulation, membrane association and secretion of tumor cathepsin B. APMIS 1999, 107:28-37.
75. Kos J., Werle B., Lah T., Brunner N. Cysteine proteinases and their inhibitors in extracellular fluids: Markers for diagnosis and prognosis in cancer. Int. J. Biol. Markers 2000, 15:84-89.
76. Everts V., van der Zee E., Creemers L., Beertsen W. Phagocytosis and intracellular digestion of collagen, its role in turnover and remodelling. Histochem. J. 1996, 28:229-245.
77. Arora P.D., Manolson M.F., Downey G.P., Sodek J., McCulloch C.A. A novel model system for characterization of phagosomal maturation, acidification, and intracellular collagen degradation in fibroblasts. J. Biol. Chem. 2000, 275:35432-35441.
78. Segal G., Lee W., Arora P.D., McKee M., Downey G., McCulloch C.A. Involvement of actin filaments and integrins in the binding step in collagen phagocytosis by human fibroblasts. J. Cell Sci. 2001, 114:119-129.
79. Sloane B.F., Rozhin J., Johnson K., Taylor H., Crissman J.D., Honn K.V. Cathepsin B: Association with plasma membrane in metastatic tumors. Proc. Natl. Acad. Sci. USA 1986, 83:2483-2487.
80. Rozhin J., Wade R.L., Honn K.V., Sloane B.F. Membrane-associated cathepsin L: A role in metastasis of melanomas. Biochem. Biophys. Res. Commun. 1989, 164:556-561.
81. Sameni M., Moin K., Sloane B.F. Imaging proteolysis by living human breast cancer cells. Neoplasia 2000, 2:496-504.
82. Gelb B.D., Shi G.P., Chapman H.A., Desnick R.J. Pycnodysostosis, a lysosomal disease caused by cathepsin K defi ciency. Science 1996, 273:1236-1238.
83. Saftig P., Hunziker E., Wehmeyer O., Jones S., Boyde A., Rommerskirch W., Moritz J.D., Schu P., von Figura K. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. USA 1998, 95:13453-13458.
84. Giranda V.L., Matrisian L.M. The protease consortium: an alliance to advance the understanding of proteolytic enzymes as therapeutic targets for cancer. Mol. Carcinog. 1999, 26:139-142.
85. Davie E.W., Fujikawa K., Diesel W. The coagulation cascade: Initiation, maintenance, and regulation. Biochemistry 1991, 30:10363-10370.
86. Donati M.B. Cancer and thrombosis: From Phlegmasia Alba Dolens to transgenic mice. Thrombosis Haemostasis 1995, 74:278-281.
87. Dvorak H.F., Nagy J.A., Berse B., Brown L.F., Yeo K.-T., Yeo T.-K., Dvorak A.M., van de Water L., Siousat T.M., Senger D.R. Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann. N. Y. Acad. Sci. 1992, 667:101-111.
88. Colucci M., Delaini F., de Bellis Vitti G., Locati D., Poggi A., Semeraro N., Donati M.B. Warfarin inhibits both procoagulant activity and metastatic capacity of Lewis lung carcinoma cells: Role of vitamin K deficiency. Biochem. Pharmacol. 1983, 32:1689-1691.
89. Esumi N., Fan D., Fidler I.J. Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res. 1991, 51:4549-4556.
90. Fischer E.G., Ruf W.R., Mueller B.M. Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. Cancer Res. 1995, 55:1629-1632.
91. Mueller B.M., Reisfeld R.A., Edginton T.S., Ruf W. Expression of tissue factor by melanoma cells promotes efficient metastasis. Proc. Natl. Acad. Sci. USA 1992, 89:11832-11836.
92. Tuszynski G.P., Gasic T.B., Gasic G.J. Isolation and characterization of antistasin. J. Biol. Chem. 1987, 262:9718-9723.
93. Palumbo J.S., Kombrinck K.W., Drew A.F., Grimes T.S., Kiser J.H., Degen J.L., Bugge T.H. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000, 96:3302-3309.
94. Tanimoto H., Underwood L.J., Wang Y., Shigemasa K., Parmley T.H., O'Brien T.J. Ovarian tumor cells express a transmembrane serine protease: A potential candidate for early diagnosis and therapeutic intervention. Tumour Biol. 2001, 22:104-114.
95. Underwood L.J., Shigemasa K., Tanimoto H., Beard J.B., Schneider E.N., Wang Y., Parmley T.H., O'Brien T.J. Ovarian tumor cells express a novel multi-domain cell surface serine protease. Biochim Biophys Acta 2000, 1502:337-350.
96. Wallrapp C., Hahnel S., Muller-Pillasch F., Burghardt B., Iwamura T., Ruthenburger M., Lerch M.M., Adler G., Gress T.M. A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer. Cancer Res. 2000, 60:2602-2606.
97. Chen Z.L., Yoshida S., Kato K., Momota Y., Suzuki J., Tanaka T., Ito J., Nishino H., Aimoto S., Kiyama H. Expression and activity-dependent changes of a novel limbic-serine protease gene in the hippocampus. J. Neurosci. 1995, 15:5088-5097.
98. Davies B.J., Pickard B.S., Steel M., Morris R.G., Lathe R. Serine proteases in rodent hippocampus. J. Biol. Chem. 1998, 273:23004-23011.
99. Underwood L.J., Tanimoto H., Wang Y., Shigemasa K., Parmley T.H., O'Brien T.J. Cloning of tumor-associated differentially expressed gene-14, a novel serine protease overexpressed by ovarian carcinoma. Cancer Res. 1999, 59:4435-4439.
100. Magklara A., Scorilas A., Katsaros D., Massobrio M., Yousef G.M., Fracchioli S., Danese S., Diamandis E.P. The human KLK8 (neuropsin/ovasin) gene: Identification of two novel splice variants and its prognostic value in ovarian cancer. Clin. Cancer Res. 2001, 7:806-811.
101. Yamashiro K., Tsuruoka N., Kodama S., Tsujimoto M., Yamamura Y., Tanaka T., Nakazato H., Yamaguchi N. Molecular cloning of a novel trypsin-like serine protease (neurosin) preferentially expressed in brain. Biochim. Biophys. Acta 1997, 350:11-14.
102. Little S.P., Dixon E.P., Norris F., Buckley W., Becker G.W., Johnson M., Dobbins J.R., Wyrick T., Miller J.R., MacKellar W., Hepburn D., Corvalan J., McClure D., Liu X., Stephenson D., Clemens J., Johnstone E.M. Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain. J. Biol. Chem. 1997, 272:25135-25142.
103. Anisowicz A., Sotiropoulou G., Stenman G., Mok S.C., Sager R. A novel protease homolog differentially expressed in breast and ovarian cancer. Mol. Med. 1996, 5:624-636.
104. Matsui H., Kimura A., Yamashiki N., Moriyama A., Kaya M., Yoshida I., Takagi N., Takahashi T. Molecular and biochemical characterization of a serine proteinase predominantly expressed in the medulla oblongata and cerebellar white matter of mouse brain. J. Biol. Chem. 2000, 275:11050-11057.
105. Meier N., Dear T.N., Boehm T.A. Novel serine protease overexpressed in the hair follicles of nude mice. Biochem. Biophys. Res. Commun. 1999, 258:374-378.
106. Scarisbrick I.A., Towner M.D., Isackson P.J. Nervous system-specific expression of a novel serine protease: Regulation in the adult rat spinal cord by excitotoxic injury. J. Neurosci. 1997, 17:8156-8168.
107. Hansson L., Stromqvist M., Backman A., Wallbrandt P., Carlstein A., Egelrud T. Cloning, expression, and characterization of stratum corneum chymotryptic enzyme: A skin-specific human serine proteinase. J. Biol. Chem. 1994, 269:19420-19426.
108. Leytus S.P., Loeb K.R., Hagen F.S., Kurachi K., Davie E.W. A novel trypsin-like serine protease (hepsin) with a putative transmembrane domain expressed by human liver and hepatoma cells. Biochemistry 1988, 27:1067-1074.
109. Paoloni-Giacobino A., Chen H., Peitsch M.C., Rossier C., Antonarakis S.E. Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3. Genomics 1997, 44:309-320.
110. Zhang Y., Cai X., Schlegelberger B., Zheng S. Assignment of human putative tumor suppressor genes ST13 (alias SNC6) and ST14 (alias SNC19) to human chromosome bands 22q13 and 11q24->q25 by in situ hybridization. Cytogenet. Cell Genet. 1998, 83:56-57.
111. Takeuchi T., Shuman M.A., Craik C.S. Reverse biochemistry: Use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc. Natl. Acad. Sci. USA 1999, 96:11054-11061.
112. Lin C.Y., Anders J., Johnson M., Sang Q.A., Dickson R.B. Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J. Biol. Chem. 1999, 274:18231-18236.
113. Kim M.G., Chen C., Lyu M.S., Cho E.G., Park D., Kozak C., Schwartz R.H. Cloning and chromosomal mapping of a gene isolated from thymic stromal cells encoding a new mouse type II membrane serine protease, epithin, containing four LDL receptor modules and two CUB domains. Immunogenetics 1999, 49:420-428.
114. Hooper J.D., Nicol D.L., Dickinson J.L., Eyre H.J., Scarman A.L., Normyle J.F., Stuttgen M.A., Douglas M.L., Loveland K.A., Sutherland G.R., Antalis T.M. Testisin, a new human serine proteinase expressed by premeiotic testicular germ cells and lost in testicular germ cell tumors. Cancer Res. 1999, 59:3199-3205.
115. Inoue M., Kanbe N., Kurosawa M., Kido H. Cloning and tissue distribution of a novel serine protease esp-1 from human eosinophils. Biochem. Biophys. Res. Commun. 1998, 18:307-312.
116. Niedermeyer J., Scanlan M.J., Garin-Chesa P., Daiber C., Fiebig H.H., Old L.J., Rettig W.J., Schnapp A. Mouse fibroblast activation protein: Molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers. Int. J. Cancer 1997, 71:383-389.
117. Goldstein L.A., Ghersi G., Pineiro-Sanchez M.L., Salamone M., Yeh Y., Flessate D., Chen W.T. Molecular cloning of seprase: A serine integral membrane protease from human melanoma. Biochim. Biophys. Acta 1997, 1361:11-19.
118. Diamandis E.P., Yousef G.M., Soosaipillai A.R., Bunting P. Human kallikrein 6 (zyme/protease M/neurosin): A new serum biomarker of ovarian carcinoma. Clin. Biochem. 2000, 33:579-583.
119. Shigemasa K., Underwood L.J., Beard J., Tanimoto H., Ohama K., Parmley T.H., O'Brien T.J. Overexpression of testisin, a serine protease expressed by testicular germ cells, in epithelial ovarian tumor cells. J. Soc. Gynecol. Investig. 2000, 7:358-362.
120. Tanimoto H., Underwood L.J., Shigemasa K., Yan Yan M.S., Clarke J., Parmley T.H., O'Brien T.J. The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells. Cancer 1999, 86:2074-2082.
121. Dhanasekaran S.M., Barrette T.R., Ghosh D., Shah R., Varambally S., Kurachi K., Pienta K.J., Rubin M.A., Chinnaiyan A.M. Delineation of prognostic biomarkers in prostate cancer. Nature 2001, 412:822-826.
122. Welsh J.B., Sapinoso L.M., Su A.I., Kern S.G., Wang-Rodriguez J., Moskaluk C.A., Frierson H.F., Hampton G.M. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 2001, 15:5974-5978.
123. Magee J.A., Araki T., Patil S., Ehrig T., True L., Humphrey P.A., Catalona W.J., Watson M.A., Milbrandt J. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res. 2001, 61:5692-5696.
124. Luo J., Duggan D.J., Chen Y., Sauvageot J., Ewing C.M., Bittner M.L., Trent J.M., Isaacs W.B. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res. 2001, 61:4683-4688.
125. Nagy J.A., Meyers M.S., Masse E.M., Herzberg K.T., Dvorak H.F. Pathogenesis of ascites tumor growth: Fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity. Cancer Res. 1995, 55:369-375.
126. Kazama Y., Hamamoto T., Foster D.C., Kisiel W. Hepsin, a putative membrane-associated serine protease, activates human factor VII and initiates a pathway of blood coagulation on the cell surface leading to thrombin formation. J. Biol. Chem. 1995, 270:66-72.
127. Garin-Chesa P., Old L.J., Rettig W.J. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc. Natl. Acad. Sci. USA 1990, 87:7235-7239.
128. Rettig W.J., Su S.L., Fortunato S.R., Scanlan M.J., Raj B.K., Garin-Chesa P., Healey J.H., Old L.J. Fibroblast activation protein: Purification, epitope mapping and induction by growth factors. Int. J. Cancer 1994, 58:385-392.
129. Mersmann M., Schmidt A., Rippmann J.F., Wuest T., Brocks B., Rettig W.J., Garin-Chesa P., Pfizenmaier K., Moosmayer D. Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas. Int. J. Cancer 2001, 92:240-248.
130. Mann N.S., Mann S.K. Enterokinase. Proc. Soc. Exp. Biol. Med. 1994, 206:114-118.
131. Hooper J.D., Clements J.A., Quigley J.P., Antalis T.M. Type II transmembrane serine proteases: Insights into an emerging class of cell surface proteolytic enzymes. J. Biol. Chem. 2001, 276:857-860.
132. Oberst M., Anders J., Xie B., Singh B., Ossandon M., Johnson M., Dickson R.B., Lin C.Y. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am. J. Pathol. 2001, 158:1301-1311.
133. Lee S.L., Dickson R.B., Lin C.Y. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J. Biol. Chem. 2000, 275:36720-36725.
134. Takeuchi T., Harris J.L., Huang W., Yan K.W., Coughlin S.R., Craik C.S. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J. Biol. Chem. 2000, 275:26333-26342.
135. Murphy G., Stanton H., Cowell S., Butler G., Knauper V., Atkinson S., Gavrilovic J. Mechanisms for promatrix metalloproteinase activation. APMIS 1999, 107:38-44.
136. List K., Jensen O.N., Bugge T.H., Lund L.R., Ploug M., Danø K., Behrendt N. Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo: Activation of prourokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice. Biochemistry 2000, 39:508-515.
137. Romisch J., Vermohlen S., Feussner A., Stohr H. The FVII activating protease cleaves single-chain plasminogen activators. Haemostasis 1999, 29:292-299.
138. Kobayashi H., Schmitt M., Goretzki L., Chucholowski N., Calvete J., Kramer M., Gunzler W.A., Janicke F., Graeff H. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J. Biol. Chem. 1991, 266:5147-5152.
139. Strongin A.Y., Collier I., Bannikov G., Marmer B.L., Grant G.A., Goldberg G.I. Mechanism of cell surface activation of 72-kDa type IV collagenase: Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem. 1995, 270:5331-5338.
140. Cowell S., Knauper V., Stewart M.L., DOrtho M.P., Stanton H., Hembry R.M., Lopez-Otin C., Reynolds J.J., Murphy G. Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: Associated activation of gelatinase A, gelatinase B and collagenase 3. Biochem. J. 1998, 331:453-458.
141. Dumin J.A., Dickeson S.K., Stricker T.P., Bhattacharyya-Pakrasi M., Roby J.D., Santoro S.A., Parks W.C. Pro-collagenase-1 (matrix metalloproteinase-1) binds the alpha(2)beta(1) integrin upon release from keratinocytes migrating on type 1 collagen. J. Biol. Chem. 2001, 276:29368-29374.
142. Barmina O.Y., Walling H.W., Fiacco G.J., Freije J.M., Lopez-Otin C., Jeffrey J.J., Partridge N.C. Collagenase-3 binds to a specific receptor and requires the low density lipoprotein receptor-related protein for internalization. J. Biol. Chem. 1999, 274:30087-30093.
143. Yu Q., Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev. 1999, 13:35-48.
144. Ruf R., Mueller B.M. Tissue factor in cancer angiogenesis and metastasis. Curr. Opin. Hematol. 1996, 3:379-384.
145. Zacharski L.R., Wojtukiewicz M.Z., Costantini V., Ornstein D.L., Memoli V.A. Pathways of coagulation/fibrinolysis activation in malignancy. Semin. Thromb. Hemost. 1992, 18:104-116.
146. Woessner J.F., Nagase H. Matrix Metalloproteinases and TIMPSs 1996, Oxford Univ. Press, New York.
147. Lijnen H.R., Silence J., Van Hoef B., Collen D. Stromelysin-1 (MMP-3)-independent gelatinase expression and activation in mice. Blood 1998, 91:2045-2053.
148. Ramos-DeSimone N., Hahn-Dantona E., Sipley J., Nagase H., French D.L., Quigley J.P. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J. Biol. Chem. 1999, 274:13066-13076.
149. Mazzieri R., Masiero L., Zanetta L., Monea S., Onisto M., Garbisa S., Mignatti P. Control of type IV collagenase activity by components of the urokinase-plasmin system: A regulatory mechanism with cell-bound reactants. EMBO J. 1997, 16:2319-2332.
150. Carmeliet P., Moons L., Lijnen R., Baes M., Lemaitre V., Tipping P., Drew A., Eeckhout Y., Shapiro S., Lupu F., Collen D. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nature Genet. 1997, 17:439-444.
151. Knauper V., Will H., Lopez-Otin C., Smith B., Atkinson S.J., Stanton H., Hembry R.M., Murphy G. Cellular mechanisms for human procollagenase-3 (MMP-13) activation: Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J. Biol. Chem. 1996, 271:17124-17131.
152. Coussens L.M., Raymond W.W., Bergers G., Laig- Webster M., Behrendtsen O., Werb Z., Caughey G.H., Hanahan D. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 1999, 13:1382-1397.
153. Liotta L.A., Thorgeirsson U.P., Garbisa S. Role of collagenases in tumor cell invasion. Cancer Metastasis Rev. 1982, 1:277-288.
154. Lund L.R., Rømer J., Bugge T.H., Nielsen B.S., Frandsen T.L., Degen J.L., Stephens R.W., Danø K. Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J. 1999, 18:4645-4656.
155. Altieri D.C., Mannucci P.M., Capitanio A.M. Binding of fibrinogen to human monocytes. J. Clin. Invest. 1986, 78:968-976.
156. Dejana E., Languino L.R., Polentarutti N., Balconi G., Ryckewaert J.J., Larrieu M.J., Donati M.B., Mantovani A., Marguerie G. Interaction between fibrinogen and cultured endothelial cells: Induction of migration and specific binding. J. Clin. Invest. 1985, 75:11-18.
157. Sherman L.A., Lee J. Specific binding of soluble fibrin to macrophages. J. Exp. Med. 1977, 145:76-85.
158. Katagiri Y., Hiroyama T., Akamatsu N., Suzuki H., Yamazaki H., Tanoue K. Involvement of alpha v beta 3 integrin in mediating fibrin gel retraction. J. Biol. Chem. 1995, 270:1785-1790.
159. Languino L.R., Duperray A., Joganic K.J., Fornaro M., Thornton G.B., Altieri D.C. Regulation of leukocyte-endothelium interaction and leukocyte transendothelial migration by intercellular adhesion molecule 1-fibrinogen recognition. Proc. Natl. Acad. Sci. USA 1995, 92:1505-1509.
160. Simon D.I., Ezratty A.M., Francis S.A., Rennke H., Loscalzo J. Fibrin(ogen) is internalized and degraded by activated human monocytoid cells via Mac-1 (CD11b/CD18): A nonplasmin fibrinolytic pathway. Blood 1993, 82:2414-2422.
161. Dvorak H.F., Dvorak A.M., Manseau E.J., Wiberg L., Churchill W.H. Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs: Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression. J. Natl. Cancer Inst. 1979, 62:1459-1472.
162. Dvorak H.F., Harvey V.S., Estrella P., Brown L.F., McDonagh J., Dvorak A.M. Fibrin containing gels induce angiogenesis: Implications for tumor stroma generation and wound healing. Lab. Invest. 1987, 57:673-686.
163. Plow E.F., Edginton T.S. Lymphocyte suppressive peptides are derived predominantly from the Aα chain. J. Immunol. 1986, 137:1910-1915.
164. Robson S.C., Saunders R., Purves L.R., de Jager C., Corrigal A., Kirch R.E. Fibrin and fibrinogen degradation products with an intact D-domain C terminal gamma chain inhibit an early step in accessory cell-dependent lymphocyte mitogenesis. Blood 1993, 81:3006-3014.
165. Skogen W.F., Senoir R.M., Griffin G.L., Wilner G.D. Fibrinogen-derived peptide Bb1-42 is a multidomain neutrophil chemoattractant. Blood 1988, 71:1475-1479.
166. Thompson W.D., Smoth E.B., Stirk C.M., Wang J. Fibrin degradation products in growth stimulatory extracts of pathological lesions. Blood Coagul. Fibrinolysis 1993, 4:113-115.
167. Cavenaugh P.G., Sloane B.F., Honn K.V. Role of the coagulation system in tumor-cell-induced platelet aggregation and metastasis. Haemostasis 1988, 18:37-46.
168. Chew E.C., Wallace A.C. Demonstration of fibrin in early stages of metastasis. Cancer Res. 1976, 36:1904-1909.
169. Crissman J.D., Hatfield J.S., Menter D.G., Sloane B.S., Honn K.V. Morphological studies of the interaction of intravascular tumor cells with endothelial cells and subendothelial matrix. Cancer Res. 1988, 48:4065-4072.
170. Werb Z. ECM and cell surface proteolysis: Regulating cellular ecology. Cell 1997, 91:439-442.
171. McCawley L.J., Matrisian L.M. Matrix metalloproteinases: They're not just for matrix anymore!. Curr. Opin. Cell Biol. 2001, 13:534-540.
172. Rifkin D.B., Mazzieri R., Munger J.S., Noguera I., Sung J. Proteolytic control of growth factor availability. APMIS 1999, 107:80-85.
173. Whitelock J.M., Murdoch A.D., Iozzo R.V., Underwood P.A. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J. Biol. Chem. 1996, 271:10079-10086.
174. Martin D.C., Fowlkes J.L., Babic B., Khokha R. Insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1. J. Cell Biol. 1999, 146:881-892.
175. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2000, 2:737-744.
176. Pilcher B.K., Dumin J.A., Sudbeck B.D., Krane S.M., Welgus H.G., Parks W.C. The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix. J. Cell Biol. 1997, 137:1445-1457.
177. Messent A.J., Tuckwell D.S., Knauper V., Humphries M.J., Murphy G., Gavrilovic J. Effects of collagenase-cleavage of type I collagen on alpha2beta1 integrin-mediated cell adhesion. J. Cell Sci. 1998, 111:1127-1135.
178. Giannelli G., Falk-Marzillier J., Schiraldi O., Stetler-Stevenson W.G., Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997, 277:225-228.
179. Koshikawa N., Giannelli G., Cirulli V., Miyazaki K., Quaranta V. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J. Cell Biol. 2000, 148:615-624.
180. Montgomery A.M., Reisfeld R.A., Cheresh D.A. Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc. Natl. Acad. Sci. USA 1994, 91:8856-8860.
181. Lochter A., Galosy S., Muschler J., Freedman N., Werb Z., Bissell M.J. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J. Cell Biol. 1997, 139:1861-1872.
182. Ho A.T., Voura E.B., Soloway P.D., Watson K.L., Khokha R. MMP inhibitors augment fibroblast adhesion through stabilization of focal adhesion contacts and upregulation of cadherin function. J. Biol. Chem. 2001, 276:40215-40224.
183. Rømer J., Pyke C., Lund L.R., Ralfkiaer E., Danø K. Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin. J. Invest. Dermatol. 2001, 116:353-358.
184. Schmidt M., Hoppe F. Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients. Acta Otolaryngol. 1999, 119:949-953.
185. Yasuda T., Sakata Y., Kitamura K., Morita M., Ishida T. Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck. Head Neck 1997, 19:611-616.
186. Itaya T. Relationship between head and neck squamous cell carcinomas and fibrinolytic factors: Immunohistological study. Acta Otolaryngol. Suppl. 1996, 525:113-119.
187. Bjorlin G., Ljungner H., Wennerberg J., Astedt B. Plasminogen activators in human xenografted oro-pharyngeal squamous cell carcinomas. Acta Otolaryngol. 1987, 104:568-572.
188. Miyajima Y., Nakano R., Morimatsu M. Analysis of expression of matrix metalloproteinases-2 and -9 in hypopharyngeal squamous cell carcinoma by in situ hybridization. Ann. Otol. Rhinol. Laryngol. 1995, 104:678-684.
189. Okada A., Bellocq J.P., Rouyer N., Chenard M.P., Rio M.C., Chambon P., Basset P. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc. Natl. Acad. Sci. USA 1995, 92:2730-2734.
190. Birkedal-Hansen B., Pavelic Z.P., Gluckman J.L., Stambrook P., Li Y.Q., Stetler-Stevenson W.G. MMP and TIMP gene expression in head and neck squamous cell carcinomas and adjacent tissues. Oral Dis. 2000, 6:376-382.
191. Kusukawa J. Expression of matrix metalloproteinase-2 related to lymph node metastasis of oral squamous cell carcinoma: A clinicopathologic study. Am. J. Clin. Pathol. 1993, 99:18-23.
192. Muller D., Wolf C., Abecassis J., Millon R., Engelmann A., Bronner G., Rouyer N., Rio M.C., Eber M., Methlin G. Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res. 1993, 53:165-169.
193. Budihna M., Strojan P., Smid L., Skrk J., Vrhovec I., Zupevc A., Rudolf Z., Zargi M., Krasovec M., Svetic B., Kopitar-Jerala N., Kos J. Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma. Biol. Chem. Hoppe Seyler 1996, 377:385-390.
194. Johansson N. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am. J. Pathol. 1997, 151:499-508.
195. Imanishi Y. Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma. Hum. Pathol. 2000, 31:895-904.
196. Kawada A., Hara K., Kominami E., Kobayashi T., Hiruma M., Ishibashi A. Cathepsin B and D expression in squamous cell carcinoma. Br. J. Dermatol. 1996, 135:905-910.
197. Zeillinger R., Eder S., Schneeberger C., Ullrich R., Speiser P., Swoboda H. Cathepsin D and PAI-1 expression in human head and neck cancer. Anticancer Res. 1996, 16:449-453.
198. Kos J. Lysosomal proteases cathepsins D, B, H, L and their inhibitors stefins A and B in head and neck cancer. Biol. Chem. Hoppe Seyler 1995, 376:401-405.
199. Yoshizaki T., Maruyama Y., Sato H., Furukawa M. Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int. J. Cancer 2001, 95:44-50.
200. Strojan P., Strojan P., Budihna M., Smid L., Vrhovec I., Skrk J. Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: Analysis of their prognostic significance in squamous cell carcinoma of the head and neck. Anticancer Res. 2000, 20:3975-3981.